CytoSorbents Plans Robust Agenda at ISICEM 2015

MONMOUTH JUNCTION, N.J., March 13, 2015 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy commercializing its CytoSorb® extracorporeal cytokine adsorber to purify blood and control severe inflammation, today announced its agenda for the 35^th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2015), March 17-20, 2015, in Brussels, Belgium.  ISICEM is among the largest annual conferences for intensive care and emergency medicine, attracting more than 6,200 participants from countries worldwide.  

Dr. Phillip Chan, Chief Executive Officer of CytoSorbents stated, "CytoSorb® is truly an international therapy, with CE Mark approval in the European Union and distribution expanding to more than 29 countries throughout the world.  Our increased presence and participation at leading clinical conferences such as ISICEM, underscores our commitment as an emerging leader in critical care immunotherapy to 1) Support our customers with the generation of clinical data 2) Promote relevant educational content, and most importantly, 3) Work together to identify and highlight best practices for CytoSorb® treatment. These activities synergize with the recent launch of the International CytoSorb® Registry and our new CytoSorb® Therapy website, both central repositories of the most up-to-date information on CytoSorb®."

The First International CytoSorb® Users Meeting
Monday, March 16, 2015, 4:00 – 9:00 PM CET, Hitchcock Auditorium
Hotel Marivaux - Boulevard Adolphe Max 98, 1000 Brussels, Belgium

In advance of ISICEM, members of the CytoSorb® community from around the world will gather at Hotel Marivaux to learn about and discuss some of the most recent advances and knowledge in CytoSorb® treatment for critical illnesses. The agenda is led by presentations from 9 distinguished international speakers focused on CytoSorb's mechanism of action, timing of intervention, and treatment experiences in sepsis, post-operative inflammation, and others.  A full program of the Users Meeting is available here.

In addition, Prof. Dr. med. Frank Brunkhorst, Director for the Center of Clinical Trials at the Paul Martini Research Unit of the University of Jena - Germany, will also introduce CytoSorb® users to the International CytoSorb Registry, independently managed by his group.  The registry will collect CytoSorb® treatment data to help assess the long-term benefits of CytoSorb® across a variety of indications, while helping to optimize CytoSorb® treatment and monitor safety.  More information about the objectives of the registry can be found here.

CytoSorbents Research Symposium at ISICEM
Thursday, March 19, 2015, 12:30 to 1:30 PM CET, Arc Room
Square - Brussels Meeting Center – rue Mont des Arts, 1000 Brussels, Belgium

CytoSorbents will also sponsor a lunch symposium entitled, "SIRS and SEPSIS: Regain control with cytokine adsorption," on-site at the conference.  The esteemed presenters and topics include: 

• From cytokine removal to modulating inflammation - the rationale for CytoSorb® therapy
  Dr. John A. Kellum, M.D., Professor and Vice Chair for Research – Critical Care Medicine
  University of Pittsburgh Medical Center (UPMC) - USA
• CytoSorb® therapy in septic shock patients - when to start?
  Dr. med. Axel Nierhaus, M.D., EDIC, Senior Consultant – Critical Care Intensivist
  University Medical Center Hamburg-Eppendorf - Germany
• Clinical effects of CytoSorb® therapy in different patient conditions
  Prof. Dr. Zsolt Molnar, Department Head - Anesthesiology and Intensive Therapy
  University of Szeged - Hungary

More information about the symposium is available here.

CytoSorbents ISICEM Exhibition Booth
March 17 - 20, 2015:  Silver Foyer, Level 0, Booth S.01 – At ISICEM

ISICEM attendees can visit CytoSorbents to learn how the CytoSorb® extracorporeal cytokine adsorber may help them regain control of their patients suffering from a dangerous maladaptive systemic inflammatory response syndrome (SIRS) in critical illnesses and cardiac surgery, with the goal of preventing or treating deadly multiple organ failure.

AT A GLANCE: CYTOSORBENTS at ISICEM

First International CytoSorb® Users Meeting
March 16, 2015, 4:00 PM CET
Hitchcock Auditorium
Hotel Marivaux, Brussels

Scientific Lunch Symposium
March 19, 2015, 12:30 PM CET
SIRS and SEPSIS: Regain control with cytokine adsorption
The Arc Room – Square-Brussels Meeting Center

CytoSorbents Conference Exhibition
March 17-20, 2015
Square-Brussels Meeting Center, Silver Foyer, Booth S.01

About ISICEM

The International Symposium on Intensive Care and Emergency Medicine is organized by the Departments of Intensive Care and Emergency Medicine of Erasme University Hospital, Universite Libre de Bruxelles, in association with the Belgian Society of Intensive Care and Emergency Medicine. This annual conference was started in 1980 and has become established as one of the largest in its field, now attracting more than 6,000 participants from countries worldwide. The objectives of this four-day symposium are to provide participants with an up-to-date review of the most recent, clinically relevant, developments in research, therapy, and management of the critically ill. The meeting is open to all physicians, nurses, and other health professionals with an interest in critical care or emergency medicine.

About CytoSorbents  

CytoSorbents Corporation is a critical care focused immunotherapy company using blood purification to control severe inflammation -- with the goal of preventing multiple organ failure in life-threatening conditions. Organ failure is the irreversible cause of nearly half of all deaths in the intensive care unit. CytoSorb®, the Company's flagship product, is approved in the European Union and marketed in 29 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in prevalent critical care scenarios such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications including multiple organ failure.

CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information can be found at: http://www.cytosorbents.com.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 31, 2014, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

Please Click to Follow us on Facebook and Twitter

Logo - http://photos.prnewswire.com/prnh/20140408/MM00899LOGO

SOURCE CytoSorbents Corporation

Related Links

http://www.cytosorb.com